Table 3.

EET in the tiotropium/olodaterol pooled group at week 6 versus baseline and in the tiotropium/olodaterol pooled group versus placebo group at week 6.

T/O at week 6 versus baseline
	Arithmetic mean					Geometric mean
	EET, s (SE)		Change from baseline			EET, s (SE)		Ratio of EET at week 6 versus baseline
	Baseline	Week 6	Mean	95% CI	p value	Baseline	Week 6	Mean	95% CI	p value
CWRCE (n = 103)	418.6 (18.8)	507.0 (27.0)	88.4	44.0–132.8	0.0001	372.0 (19.0)	441.7 (23.2)	1.187	1.078–1.308	0.0006
ESWT (n = 103)	358.6 (20.2)	457.2 (30.3)	98.6	48.7–148.6	0.0002	305.9 (17.3)	368.3 (24.1)	1.204	1.077–1.346	0.0013
T/O versus placebo at week 6
	Arithmetic mean					Geometric mean
	EET, s (SE)		Change from placebo			EET, s (SE)		Ratio of EET with T/O at week 6 versus placebo
	Placebo	T/O	Mean	95% CI	p value	Placebo	T/O	Mean	95% CI	p value
CWRCE	425.2 (25.3)	507.0 (27.0)	118.3	45.9–190.8	0.0015	390.3 (24.9)	441.7 (23.2)	1.223	1.054–1.420	0.0083
ESWT	375.6 (34.0)	457.2 (30.3)	76.3	−2.8–155.4	0.0585	316.0 (27.4)	368.3 (24.1)	1.165	0.979–1.387	0.0856

CI, confidence interval; CWRCE, constant work rate cycle ergometry; EET, exercise endurance time; ESWT, endurance shuttle walk test; s, seconds; SE, standard error of the mean; T/O, tiotropium/olodaterol.